






1/7

*Fig. 1**Fig. 2*

2/7

*Fig. 3A**Fig. 3B**Fig. 5*








Fig. 4

4/7

*Fig. 6**Fig. 7*

*Fig. 8*

\*MTX is significantly different from control for the rest of the protocol.

\*\*Compound 1 is significantly different from the control.

*Fig. 9*

6/7





Fig. 10



Inflammation significantly inferior to control

Compound 19a IV: Days 1, 2, 3, 4, 5, 6, 12, 13, 14, 15, 16, 18 and 19

MTX: Days 5, 15, 16, 17, 18, 19 and 21

Compound 19a PO: Days 1, 3, 5 and 6

Compound 1 PO: Days 4, 5 and 16

Compound 1 IV: Days 16 and 19

◆ Control  
 ■ MTX  
 ▲ Compound 1-IV  
 ■ Compound 19a-IV  
 \* Compound 1-PO  
 ○ Compound 19a-PO

Fig. 11

7/7




Fig. 12




Fig. 13